Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy

Scandinavian Journal of Pain

Volumn 4, Issue 2, 2013, Pages 77-83

  Kalliomäki, Jarkko ^a   Jonzon, Bror ^a   Huizar, Karin ^a   O'Malley, Michael ^a   Andersson, Anita ^a   Simpson, David M ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CCR2; CCR2 antagonist; Chemokines; Diabetic neuropathy; Neuropathic pain; Randomized controlled trial

Indexed keywords

AZD 2423; CHEMOKINE RECEPTOR CCR2; HEMOGLOBIN A1C; PLACEBO;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; EVOKED SOMATOSENSORY RESPONSE; FEMALE; FEVER; HEADACHE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN SYMPTOM INVENTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUMERICAL RATING SCALE; PAIN ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY;

EID: 84876124600     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2012.10.003     Document Type: Article

References (25)

1. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
2. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009, 8:23-33.
3. Semple B.D., Kossmann T., Morganti-Kossmann M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 2010, 30:459-473.
4. Struthers M., Pasternak A. CCR2 antagonists. Curr Top Med Chem 2010, 10:1278-1298.
5. Abbadie C., Lindia J.A., Cumiskey A.M., Peterson L.B., Mudgett J.S., Bayne E.K., DeMartino J.A., MacIntyre D.E., Forrest M.J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 2003, 100:7947-7952.
6. White F.A., Sun J., Waters S.M., Ma C., Ren D., Ripsch M., Steflik J., Cortright D.N., LaMotte R.H., Miller R.J. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA 2005, 102:14092-14097.
7. White F.A., Jung H., Miller R.J. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007, 104:20151-20158.
8. Sun J.H., Yang B., Donnelly D.F., Ma C., LaMotte R.H. MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol 2006, 96:2189-2199.
9. Belkouch M., Dansereau M.A., Réaux-Le Goazigo A., Van Steenwinckel J., Beaudet N., Melik-Parsadaniantz S., Sarret P. The chemokine CCL2 increase Nav1.8 sodium channel activity in primary sensory neurons through a Gβγ-dependent mechanism. J Neurosci 2011, 31:18381-18390.
10. Zhang J., De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 2006, 97:772-783.
11. Van Steenwinckel J., Réaux-Le Goazigo A., Pommier B., Mauborgne A., Dansereau M.A., Kitabgi P., Sarret P., Pohl M., Melik-Parsadaniantz S. CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci 2011, 31:5865-5875.
12. Thacker M.A., Clark A.K., Bishop T., Grist J., Yip P.K., Moon L.D.F., Thompson S.W.F., Marchand F., McMahon S.B. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 2009, 13:263-272.
13. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A.M., Eschalier A., Fialip J. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and glia via N-methyl-d-aspartate-dependent mechanisms. Mol Pharmacol 2006, 70:1246-1254.
14. Tsuda M., Ueno H., Kataoka A., Tozaki-Saitoh H., Inoue K. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 2008, 56:378-386.
15. Suzuki N., Hasegawa-Moriyama M., Takahashi Y., Kamikubo Y., Sakurai T., Inada E. Lidocaine attenuates the development of diabetic-induced tactile allodynia by inhibiting microglial activation. Anesth Analg 2011, 113:941-946.
16. Serrano A., Paré M., McIntosh F., Elmes S., Martino G., Jomphe C., Lessard E., Lembo P., Vaillancourt F., Perkins M.N., Cao C.Q. Blocking spinal CCR2 with AZ889 reversed hyperalgesia in a model of neuropathic pain. Mol Pain 2010, 6:90.
17. Bouhassira D., Attal N., Fermanian J., Alchaar H., Gautron M., Masquelier E., Rostaing S., Lanteri-Minet M., Collin E., Grisart J., Boureau F. Development and validation of the neuropathic pain symptom inventory. Pain 2004, 108:248-257.
18. Geber C., Klein T., Azad S., Birklein F., Gierthmuhlen J., Huge V., Lauchart M., Nitzsche D., Stengel M., Valet M., Baron R., Maier C., Tölle T., Treede R.D. Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study. Pain 2011, 152:548-556.
19. Dworkin R.H., Turk D.C., Peirce-Sandner S., Baron R., Bellamy N., Burke L.B., Chappell A., Chartier K., Cleeland C.S., Costello A., Cowan P., Dimitrova R., Ellenberg S., Farrar J.T., French J.A., Gilron I., Hertz S., Jadad A.R., Jay G.W., Kalliomäki J., Katz N.P., Kerns R.D., Manning D.C., McDermott M.P., McGrath P., Narayana A., Porter L., Quessy S., Rappaport B.A., Rauschkolb C., Reeve B., Rhodes T., Sampaio C., Simpson D.M., Stauffer J.W., Stucki G., Tobias J., White R.E., Witter J. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010, 149:177-193.
20. Maier C., Baron R., Tölle T.R., Binder A., Birbaumer N., Birklein F., Giertmuhlen J., Flor H., Geber C., Huge V., Krumova E.K., Landwehrmeyer G.B., Magerl W., Maihöfner C., Richter H., Rolke R., Scherens A., Schwarz A., Sommer C., Tronnier V., Uceyler N., Valet M., Wasner G., Treede R.D. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010, 150:439-450.
21. Berge O.G. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol 2011, 164:1195-1206.
22. Attal N., Fermanian C., Fermanian J., Lanteri-Minet M., Alchaar H., Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?. Pain 2008, 138:343-353.
23. Kalliomäki J., Miller F., Kågedal M., Karlsten R. Early phase drug development for treatment of chronic pain - options for clinical trial and program design. Contemp Clin Trials 2012, 33:689-699.
24. Vergunst C.E., Gerlag D.M., Lopatinskaya L., Klareskog L., Smith M.D., van den Bosch F., Dinant H.J., Lee Y., Wyant T., Jacobson E.W., Baeten D., Tak P.P. Modulation of CCR2 in rheumatoid arthritis. A double-blind, randomized placebo-controlled clinical trial. Arthritis Rheum 2008, 58:1931-1939.
25. Tsou C.L., Peters W., Si Y., Slaymaker S., Aslanian A.M., Weisberg S.P., Mack M., Charo I.F. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007, 117:902-909.